New tuberculosis vaccines | Enfermedades Infecciosas y Microbiología Clínica

Article information

Abstract

The current tuberculosis (TB) vaccine, bacille Calmette-Guerin (BCG), is a live vaccine used worldwide, as it protects against severe forms of the disease, saving thousands of lives every year, but its efficacy against pulmonary forms of TB, responsible for transmission of the diseases, is variable.

For more than 80 years now no new TB vaccines have been successfully developed. Over the last decade the effort of the scientific community has resulted in the design and construction of promising vaccine candidates. The goal is to develop a new generation of vaccines effective against respiratory forms of the disease. We will focus this review on new prophylactic vaccine candidates that aim to prevent TB diseases.

Two are the main strategies used to improve the immunity conferred by the current BCG vaccine, by boosting it with new subunit vaccines, and a second strategy is focused on the construction of new more effective live vaccines, capable to replace the current BCG and to be used as prime vaccines.

After rigorous preclinical studies in different animal models new TB vaccine candidates enter in clinical trials in humans. First, a small Phase I for safety followed by immunological evaluation in Phase II trials and finally evaluated in large population Phase III efficacy trials in endemic countries. At present BCG prime and boost with different subunit vaccine candidates are the more advanced assessed in Phase II. Two prime vaccines (based on recombinant BCG) have been successfully evaluated for safety in Phase I trials. A short number of live attenuated vaccines are in advance preclinical studies and the candidates ready to enter Phase I safety trials are produced under current good manufacturing practices.

Keywords:

Bacille Calmette-Guerin (BCG)

Tuberculosis

Subunit vaccines

Live vaccines

Resumen

La actual vacuna contra la tuberculosis, bacilo de Calmette-Guerin (BCG), en uso desde 1921, protege contra las formas más graves de la enfermedad, pero su eficacia es muy variable contra las formas de tuberculosis pulmonar, por lo que la investigación y desarrollo de nuevas vacunas es un reto importante para la comunidad científica.

En la última década, importantes esfuerzos en investigación han dado como resultado el diseño y construcción de nuevos candidatos a vacunas contra la tuberculosis. El objetivo es desarrollar una nueva generación de vacunas eficaces contra las formas respiratorias de la enfermedad, responsables de la transmisión de la tuberculosis.

Esta revisión se centra en el progreso preclínico y clínico de nuevas vacunas profilácticas, dirigidas a prevenir la enfermedad. Dos son las principales estrategias: la primera busca mejorar la inmunidad conferida por BCG, revacunando con vacunas subunidades, y la segunda estrategia se centra en la construcción de nuevas vacunas vivas más eficaces, capaces de sustituir la actual BCG.

Tras rigurosos estudios preclínicos en modelos animales, algunos candidatos a la vacuna contra la tuberculosis han entrado en ensayos clínicos en humanos. Actualmente, las vacunas subunidades son las más avanzadas en estos ensayos y están siendo evaluadas en fase II en individuos previamente vacunados con BCG. Vacunas vivas basadas en BCG recombinante se están evaluado en fase I, y nuevas vacunas vivas atenuadas han mostrado buenos resultados de atenuación y protección en estudios preclínicos, y están listas para entrar en ensayos de fase I en humanos.

Palabras clave:

Bacilo de Calmette-Guérin (BCG)

Tuberculosis

Vacunas subunidades

Vacunas vivas atenuadas

Full text is only aviable in PDF

References

[1.]

J.W. Almond.

Vaccine renaissance.

Nat Rev Microbiol, 5 (2007), pp. 478-481

http://dx.doi.org/10.1038/nrmicro1702 | Medline

[2.]

P.E. Fine.

Variation in protection by BCG: implications of and for heterologous immunity.

Lancet, 346 (1995), pp. 1339-1345

Medline

[3.]

B.B. Trunz, P. Fine, C. Dye.

Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.

Lancet, 367 (2006), pp. 1173-1180

http://dx.doi.org/10.1016/S0140-6736(06)68507-3 | Medline

[4.]

E. Bonifachich, M. Chort, A. Astigarraga, N. Díaz, B. Brunet, S.M. Pezzotto, et al.

Protective effect of Bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina.

Vaccine, 24 (2006), pp. 2894-2899

http://dx.doi.org/10.1016/j.vaccine.2005.12.044 | Medline

[5.]

C. Demangel, T. Garnier, I. Rosenkrands, S.T. Cole.

Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens.

Infect Immun, 73 (2005), pp. 2190-2196

http://dx.doi.org/10.1128/IAI.73.4.2190-2196.2005 | Medline

[6.]

N.E. Aronson, M. Santosham, G.W. Comstock, R.S. Howard, L.H. Moulton, E.R. Rhoades, et al.

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study.

Jama, 291 (2004), pp. 2086-2091

http://dx.doi.org/10.1001/jama.291.17.2086 | Medline

[7.]

K. Ewer, J. Deeks, L. Álvarez, G. Bryant, S. Waller, P. Andersen, et al.

Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak.

Lancet, 361 (2003), pp. 1168-1173

[8.]

M. Eisenhut, S. Paranjothy, I. Abubakar, S. Bracebridge, M. Lilley, R. Mulla, et al.

BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay.

Vaccine, 27 (2009), pp. 6116-6120

http://dx.doi.org/10.1016/j.vaccine.2009.08.031 | Medline

[9.]

C. Vilaplana, E. Montane, S. Pinto, A.M. Barriocanal, G. Domenech, F. Torres, et al.

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

Vaccine, 28 (2010), pp. 1106-1116

http://dx.doi.org/10.1016/j.vaccine.2009.09.134 | Medline

[10.]

D. Young, C. Dye.

The development and impact of tuberculosis vaccines.

Cell, 124 (2006), pp. 683-687

http://dx.doi.org/10.1016/j.cell.2006.02.013 | Medline

[11.]

M.A. Behr, M.A. Wilson, W.P. Gill, H. Salamon, G.K. Schoolnik, S. Rane, et al.

Comparative genomics of BCG vaccines by whole-genome DNA microarray.

Science, 284 (1999), pp. 1520-1523

Medline

[12.]

M.A. Behr, P.M. Small.

Has BCG attenuated to impotence?.

Nature, 389 (1997), pp. 133-134

http://dx.doi.org/10.1038/38151 | Medline

[13.]

M.A. Behr.

BCG--different strains, different vaccines?.

Lancet Infect Dis, 2 (2002), pp. 86-92

Medline

[14.]

R. Brosch, S.V. Gordon, T. Garnier, K. Eiglmeier, W. Frigui, P. Valenti, et al.

Genome plasticity of BCG and impact on vaccine efficacy.

Proc Natl Acad Sci USA, 104 (2007), pp. 5596-5601

[15.]

M. Seki, I. Honda, I. Fujita, I. Yano, S. Yamamoto, A. Koyama.

Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette-Guerin (BCG) Tokyo 172: a comparative study of BCG vaccine substrains.

Vaccine, 27 (2009), pp. 1710-1716

http://dx.doi.org/10.1016/j.vaccine.2009.01.034 | Medline

[16.]

A.S. Leung, V. Tran, Z. Wu, X. Yu, D.C. Alexander, G.F. Gao, et al.

Novel genome polymorphisms in BCG vaccine strains and impact on efficacy.

BMC Genomics, 9 (2008), pp. 413

http://dx.doi.org/10.1186/1471-2164-9-413 | Medline

[17.]

C.F. Von Reyn, L. Mtei, R.D. Arbeit, R. Waddell, B. Cole, T. Mackenzie, et al.

Prevention of tuberculosis in Bacille Calmette-Guerin-primed. HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.

Aids, 24 (2010), pp. 675-685

http://dx.doi.org/10.1097/QAD.0b013e3283350f1b | Medline

[18.]

I.M. Orme, D.N. McMurray, J.T. Belisle.

Tuberculosis vaccine development: recent progress.

Trends Microbiol, 9 (2001), pp. 115-118

Medline

[19.]

A. Williams, G.J. Hatch, S.O. Clark, K.E. Gooch, K.A. Hatch, G.A. Hall, et al.

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

Tuberculosis (Edinb), 85 (2005), pp. 29-38

[20.]

F.A. Verreck, R.A. Vervenne, I. Kondova, K.W. Van Kralingen, E.J. Remarque, G. Braskamp, et al.

MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.

PLoS ONE, 4 (2009), pp. e5264

http://dx.doi.org/10.1371/journal.pone.0005264 | Medline

[21.]

J.V. Brooks, A.A. Frank, M.A. Keen, J.T. Bellisle, I.M. Orme.

Boosting vaccine for tuberculosis.

Infect Immun, 69 (2001), pp. 2714-2717

[22.]

S.G. Reed, R.N. Coler, W. Dalemans, E.V. Tan, E.C. DeLa Cruz, R.J. Basaraba, et al.

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Proc Natl Acad Sci U.S.A., 106 (2009), pp. 2301-2306

http://dx.doi.org/10.1073/pnas.0712077106 | Medline

[23.]

K. Von Eschen, R. Morrison, M. Braun, O. Ofori-Anyinam, E. De Kock, P. Pavithran, et al.

The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans.

Hum Vaccin, 5 (2009), pp. 475-482

Medline

[24.]

J. Dietrich, C. Andersen, R. Rappuoli, T.M. Doherty, C.G. Jensen, P. Andersen.

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

J Immunol, 177 (2006), pp. 6353-6360

Medline

[25.]

J.T. Van Dissel, S.M. Arend, C. Prins, P. Bang, P.N. Tingskov, K. Lingnau, et al.

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.

Vaccine, 28 (2010), pp. 3571-3581

http://dx.doi.org/10.1016/j.vaccine.2010.02.094 | Medline

[26.]

H. McShane, A.A. Pathan, C.R. Sander, S.M. Keating, S.C. Gilbert, K. Huygen, et al.

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Nat Med, 10 (2004), pp. 1240-1244

http://dx.doi.org/10.1038/nm1128 | Medline

[27.]

K.T. Whelan, A.A. Pathan, C.R. Sander, H.A. Fletcher, I. Poulton, N.C. Alder, et al.

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.

PLoS One, 4 (2009), pp. e5934

http://dx.doi.org/10.1371/journal.pone.0005934 | Medline

[28.]

M.K. Hondalus, S. Bardarov, R. Russell, J. Chan, W.R. Jacobs Jr, B.R. Bloom.

Attenuation of and protection induced by a leucine auxotroph of Mycobacterium tuberculosis.

Infect Immun, 68 (2000), pp. 2888-2898

Medline

[29.]

D.F. Hoft, A. Blazevic, G. Abate, W.A. Hanekom, G. Kaplan, J.H. Soler, et al.

A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

J Infect Dis, 198 (2008), pp. 1491-1501

http://dx.doi.org/10.1086/592450 | Medline

[30.]

A.S. Pym, P. Brodin, L. Majlessi, R. Brosch, C. Demangel, A. Williams, et al.

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.

Nat Med, 9 (2003), pp. 533-539

http://dx.doi.org/10.1038/nm859 | Medline

[31.]

P. Brodin, L. Majlessi, R. Brosch, D. Smith, G. Bancroft, S. Clark, et al.

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.

J Infect Dis, 190 (2004), pp. 115-122

http://dx.doi.org/10.1086/421468 | Medline

[32.]

L. Grode, P. Seiler, S. Baumann, J. Hess, V. Brinkmann, A.N. Eddine, et al.

Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin.

J Clin Invest, 115 (2005), pp. 2472-2479

[33.]

S.H. Kaufmann.

Envisioning future strategies for vaccination against tuberculosis.

Nat Rev Immunol, 6 (2006), pp. 699-704

http://dx.doi.org/10.1038/nri1920 | Medline

[34.]

K.S. Rosenthal, D.H. Zimmerman.

Vaccines: all things considered.

Clin Vaccine Immunol, 13 (2006), pp. 821-829

http://dx.doi.org/10.1128/CVI.00152-06 | Medline

[35.]

C.F. Von Reyn, J.M. Vuola.

New vaccines for the prevention of tuberculosis.

Clin Infect Dis, 35 (2002), pp. 465-474

http://dx.doi.org/10.1086/341901 | Medline

[36.]

J.E. Ziegler, M.L. Edwards, D.W. Smith.

Exogenous reinfection in experimental airborne tuberculosis.

Tubercle, 66 (1985), pp. 121-128

Medline

[37.]

C. Martin, J. Timm, J. Rauzier, R. Gómez-Lus, J. Davies, B. Gicquel.

Transposition of an antibiotic resistance element in mycobacteria.

Nature, 345 (1990), pp. 739-743

http://dx.doi.org/10.1038/345739a0 | Medline

[38.]

M.G. Ranes, J. Rauzier, M. Lagranderie, M. Gheorghiu, B. Gicquel.

Functional analysis of pAL5000, a plasmid from Mycobacterium fortuitum: construction of a “mini” Mycobacterium-Escherichia coli shuttle vector.

J Bacteriol, 172 (1990), pp. 2793-2797

Medline

[39.]

W.R. Jacobs Jr, M. Tuckman, B.R. Bloom.

Introduction of foreign DNA into mycobacteria using a shuttle phasmid.

Nature, 327 (1987), pp. 532-535

http://dx.doi.org/10.1038/327532a0 | Medline

[40.]

V.K. Sambandamurthy, X. Wang, B. Chen, R.G. Russell, S. Derrick, F.M. Collins, et al.

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

Nat Med, 8 (2002), pp. 1171-1174

http://dx.doi.org/10.1038/nm765 | Medline

[41.]

V.K. Sambandamurthy, S.C. Derrick, T. Hsu, B. Chen, M.H. Larsen, K.V. Jalapathy, et al.

Mycobacterium tuberculosis DeltaRD1 Deltapan CD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis.

Vaccine, 24 (2006), pp. 6309-6320

http://dx.doi.org/10.1016/j.vaccine.2006.05.097 | Medline

[42.]

V.K. Sambandamurthy, S.C. Derrick, K.V. Jalapathy, B. Chen, R.G. Russell, S.L. Morris, et al.

Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Infect Immun, 73 (2005), pp. 1196-1203

http://dx.doi.org/10.1128/IAI.73.2.1196-1203.2005 | Medline

[43.]

J. Hinchey, S. Lee, B.Y. Jeon, R.J. Basaraba, M.M. Venkataswamy, B. Chen, et al.

Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis.

J Clin Invest, 117 (2007), pp. 2279-2288

http://dx.doi.org/10.1172/JCI31947 | Medline

[44.]

S. Samper, C. Martín, A. Pinedo, A. Rivero, J. Blázquez, F. Baquero, et al.

Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis.

Aids, 11 (1997), pp. 1237-1242

Medline

[45.]

S. Samper, C. Martín.

Spread of extensively drug-resistant tuberculosis.

Emerg Infect Dis, 13 (2007), pp. 647-648

http://dx.doi.org/10.3201/eid1304.061329 | Medline

[46.]

C. Martín, A. Williams, R. Hernández-Pando, P.J. Cardona, E. Gormley, Y. Bordat, et al.

The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs.

Vaccine, 24 (2006), pp. 3408-3419

[47.]

E. Pérez, S. Samper, Y. Bordás, C. Guilhot, B. Gicquel, C. Martín.

An essential role for phoP in Mycobacterium tuberculosis virulence.

Mol Microbiol, 41 (2001), pp. 179-187

[48.]

J. Gonzalo Asensio, C. Maia, N.L. Ferrer, N. Barilone, F. Laval, C.Y. Soto, et al.

The virulence-associated two-component PhoP-PhoR system controls the biosynthesis of polyketide-derived lipids in Mycobacterium tuberculosis.

J Biol Chem, 281 (2006), pp. 1313-1316

http://dx.doi.org/10.1074/jbc.C500388200 | Medline

[49.]

P.J. Cardona, J.G. Asensio, A. Arbues, I. Otal, C. Lafoz, O. Gil, et al.